Статины и сахарный диабет: проблема, миф или реальность?


Цитировать

Полный текст

Аннотация

Доступные на сегодняшний день данные, имеющие лишь ограниченную доказательную силу, позволяют предполагать, что при использовании статинов возможно небольшое увеличение риска развития СД. Такой эффект отмечен у всех трех наиболее часто применяемых в настоящее время статинов (розувастатина, аторвастатина и симвастатина) в отсутствие убедительных данных о различиях между приемом этих препаратов по влиянию на риск развития СД. Кроме того, доказательные данные убедительно свидетельствуют о том, что преимущества приема статинов у лиц, имеющих показания к их приему, существенно превышают возможные отрицательные эффекты, связанные с увеличением риска развития СД, который, по-видимому, развивается в первую очередь у лиц, имеющих высокий риск его развития. В любом случае, по мнению практически всех экспертов, полученные на сегодняшний день данные о возможном небольшом увеличении риска развития СД при приеме статинов в целом не влияют на тактику их использования по имеющимся показаниям в разных клинических ситуациях.

Об авторах

С. Р Гиляревский

ГБОУ ВПО РМАПО, Москва

Кафедра клинической фармакологии и терапии

М. В Голшмид

ГБОУ ВПО РМАПО, Москва

Кафедра клинической фармакологии и терапии

Список литературы

  1. US Food and Drug Administration. Statin drugs - drug safety communication: class labeling change. February 28, 2012. http://www.fda.gov/ Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm293670.htm.
  2. Rocco M.B. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012; 79: 883–93.
  3. Freeman D.J, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.
  4. Sever P.S, Dahlof B, Poulter N.R et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multi - centre randomised controlled trial. Lancet 2003; 361: 1149–58.
  5. Colhoun H.M, Betteridge D.J, Durrington P.N et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi - centre randomised placebo - controlled trial. Lancet 2004; 364: 685–96.
  6. Collins R, Armitage J, Parish S et al, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol - lowering with simvastatin in 5963 people with diabetes: a randomised placebo - controlled trial. Lancet 2003; 361: 2005–16.
  7. Ridker P.M, Danielson E, Fonseca F.A et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
  8. Shepherd J, Blauw G.J, Murphy M.B et al; PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.
  9. Rajpathak S.N, Kumbhani D.J, Crandall J et al. Statin therapy and risk of developing type 2 diabetes: a meta - analysis. Diabetes Care 2009; 32: 1924–9.
  10. Keech A, Colquhoun D, Best J et al. Secondary prevention of cardiovascular events with long - term pravastatin in patients with diabetes or impaired fasting glucose - results from the LIPID trial. Diabetes Care 2003; 26: 2713–21.
  11. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
  12. Sattar N, Preiss D, Murray H.M et al. Statins and risk of incident diabetes: a collaborative meta - analysis of randomised statin trials. Lancet 2010; 375: 735–42.
  13. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of car - diovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.
  14. Downs J.R, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.
  15. Scandinavian Simvastatin Survival Study study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
  16. Barzilay J.I, Davis B.R, Pressel S.L et al; ALLHAT Collaborative Research Group. Long - term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 2012; 5: 153–62.
  17. Tavazzi L, Maggioni A.P, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double - blind, placebo - controlled trial. Lancet 2008; 372: 1231–9.
  18. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenzanell’Infarto Miocardico). Results of the low - dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 2000; 1: 810–20.
  19. Levi Marpillat N, Macquin-Mavier I, Tropeano AI et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta - analysis. J Hypertens 2013; 31: 1073–82.
  20. Carter A.A, Gomes T, Camacho X et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013l 4; 347: f4356. doi: 10.1136/bmj.f4356.
  21. Yamakawa T, Takano T, Tanaka S et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15: 269–75.
  22. Kryzhanovski V, Gumprecht J, Zhu B et al. Atorvastatin but not pitavastatin significantly increases fasting plasma glucose in patients with type 2 diabetes and combined dyslipidemia (abstract). J Am Coll Cardiol 2011; 57: E575.
  23. Simsek S, Schalkwijk C.G, Wolffenbuttel B.H. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes – the CORALL study. Diabet Med 2012; 29: 628–31.
  24. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study - level network meta - analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–9.
  25. Lumley T. Network meta - analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313–24.
  26. Sabatine M.S, Wiviott S.D, Morrow D.A et al. High - dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004; 110 (Suppl. III): 834.
  27. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–6.
  28. Waters D.D, Ho J.E, DeMicco D.A et al. Predictors of new - onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535–45.
  29. Yousef A, Tu J.V, Wang J et al. The association of intensive statin therapy on long - term risks of cardiovascular events and diabetes following acute myocardial infarction (abstract). Circulation 2012; 125: e859.
  30. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High - dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
  31. Preiss D, Seshasai S.R, Welsh P et al. Risk of incident diabetes with intensive - dose compared with moderate - dose statin therapy: a meta - analysis. JAMA 2011; 305: 2556–64.
  32. Waters D.D, Ho J.E, Boekholdt S.M et al. Cardiovascular event reduction versus new - onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 15 (61):148–52.
  33. Ridker P.M, Pradhan A, Mac Fadyen J.G et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565–71.
  34. Brunzell J.D, Davidson M, Furberg C.D et al; American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811–22.
  35. Koh K.K, Quon M.J, Han S.H et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55:1209–16.
  36. Koh K.K, Quon M.J, Han S.H et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483–90.
  37. Nakata M, Nagasaka S, Kusaka I et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.
  38. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose - induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta - cells. Br J Pharmacol 1999; 126: 1205–13.
  39. Nakata M, Nagasaka S, Kusaka I et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).